Syndax Pharmaceuticals Inc

SNDX

23.490USD

-1.210-4.90%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Syndax Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

28 / 391

Overall Ranking

120 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Syndax Pharmaceuticals Inc Highlights

StrengthsRisks

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 172.35M.

Undervalued

The company’s latest PE is -7.13, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 103.19M shares, decreasing 15.40% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 113.08K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.62.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

40.182

Target Price

+62.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Syndax Pharmaceuticals Inc is 7.02, ranking 144 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 68.73M, representing a year-over-year increase of 794.90%, while its net profit experienced a year-over-year increase of 27.77%.

Score

Industry at a Glance

Previous score

7.02

Change

0



Financials

5.51

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

5.20

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.98

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.37

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Syndax Pharmaceuticals Inc is 6.06, ranking 334 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.13, which is -68.54% below the recent high of -2.24 and -65.39% above the recent low of -11.79.

Score

Industry at a Glance

Previous score

6.06

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 28/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Syndax Pharmaceuticals Inc is 8.86, ranking 43 out of 391 in the Biotechnology & Medical Research industry. The average price target is 38.00, with a high of 56.00 and a low of 27.00.

Score

Industry at a Glance

Previous score

8.86

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Syndax Pharmaceuticals Inc is 7.49, ranking 45 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 25.72 and the support level at 21.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.50

Change

-2.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Syndax Pharmaceuticals Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 118.73%, representing a quarter-over-quarter decrease of 2.37%. The largest institutional shareholder is The Vanguard, holding a total of 6.21M shares, representing 7.04% of shares outstanding, with 24.77% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Kynam Capital Management LP

8.52M

--

BlackRock Institutional Trust Company, N.A.

6.77M

-10.43%

The Vanguard Group, Inc.

Star Investors

5.12M

+2.09%

Goldman Sachs & Company, Inc.

4.84M

-6.78%

Point72 Asset Management, L.P.

Star Investors

4.26M

+100.01%

State Street Investment Management (US)

3.85M

+11.93%

BofA Global Research (US)

3.69M

-3.91%

Eversept Partners, LP

3.47M

-14.71%

Franklin Advisers, Inc.

2.36M

+1.27%

Kingdon Capital Management, L.L.C.

2.50M

+19.05%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Syndax Pharmaceuticals Inc is 5.56, ranking 43 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.39. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Syndax Pharmaceuticals Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Syndax Pharmaceuticals Inc

SNDX

7.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment